Ignat Drozdov

Ignat Drozdov

Auto-generated profile, based on publicly available information

Ignat Drozdov

Bering Limited, London, United Kingdom

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2010 in Circulation Research
Verified
Journal Article
Closed access
AZANNA ZAMPETAKI
ANNA ZAMPETAKI
SKStefan Kiechl
Stefan Kiechl
IDIgnat Drozdov
Ignat Drozdov
PWPeter Willeit
Peter Willeit
UMUrsula Mayr
Ursula Mayr
MMManuel Mayr
Manuel Mayr
Rationale:: MicroRNAs (miRNAs) have been implicated in the epigenetic regulation of key metabolic, inflammatory, and antiangiogenic pathways in type 2 diabetes (DM) and may contribute to common disease complications. Objective:: In this study, we explore plasma miRNA profiles in patients with DM. Methods and Results:: Total RNA was extracted from plasma samples of the prospective population-based Bruneck study. A total of 13 candidate miRNAs identified by microarray screening and miRNA network inference were quantified by quantitative PCR in all diabetic patients of the Bruneck study and age- and sex-matched controls (1995 evaluation, n=80 each). Quantitative PCR assessment revealed lower plasma levels of miR-20b, miR-21, miR-24, miR-15a, miR-126, miR-191, miR-197, miR-223, miR-320, and miR-486 in prevalent DM, but a modest increase of miR-28-3p. Findings emerged as robust in multivariable analysis and were independent of the standardization procedure applied. For endothelial miR-126, results were confirmed in the entire Bruneck cohort (n=822) in univariate (odds ratio [95% confidence interval], 0.38 [0.26 to 0.55]; P =2.72×10 −7 ) and multivariate analyses (0.57 [0.37 to 0.86]; P =0.0082). Importantly, reduced miR-15a, miR-29b, miR-126, miR-223, and elevated miR-28-3p levels antedated the manifestation of disease. Most differences in miRNA levels were replicated in plasma obtained from hyperglycemic Lep ob mice. High glucose concentrations reduced the miR-126 content of endothelial apoptotic bodies. Similarly in patients with DM, the reduction of miR-126 was confined to circulating vesicles in plasma. Conclusions:: We reveal a plasma miRNA signature for DM that includes loss of endothelial miR-126. These findings might explain the impaired peripheral angiogenic signaling in patients with DM.

10 April 2015 in Circulation Research
Verified
Journal Article
Closed access
PDF file
AKAlexander N. Kapustin
Alexander N. Kapustin
MCMartijn L.L. Chatrou
Martijn L.L. Chatrou
IDIgnat Drozdov
Ignat Drozdov
YZYing Zheng
Ying Zheng
SDSean M. Davidson
Sean M. Davidson
CSCathy Shanahan
Cathy Shanahan
Rationale:: Matrix vesicles (MVs), secreted by vascular smooth muscle cells (VSMCs), form the first nidus for mineralization and fetuin-A, a potent circulating inhibitor of calcification, is specifically loaded into MVs. However, the processes of fetuin-A intracellular trafficking and MV biogenesis are poorly understood. Objective:: The objective of this study is to investigate the regulation, and role, of MV biogenesis in VSMC calcification. Methods and Results:: Alexa488-labeled fetuin-A was internalized by human VSMCs, trafficked via the endosomal system, and exocytosed from multivesicular bodies via exosome release. VSMC-derived exosomes were enriched with the tetraspanins CD9, CD63, and CD81, and their release was regulated by sphingomyelin phosphodiesterase 3. Comparative proteomics showed that VSMC-derived exosomes were compositionally similar to exosomes from other cell sources but also shared components with osteoblast-derived MVs including calcium-binding and extracellular matrix proteins. Elevated extracellular calcium was found to induce sphingomyelin phosphodiesterase 3 expression and the secretion of calcifying exosomes from VSMCs in vitro, and chemical inhibition of sphingomyelin phosphodiesterase 3 prevented VSMC calcification. In vivo, multivesicular bodies containing exosomes were observed in vessels from chronic kidney disease patients on dialysis, and CD63 was found to colocalize with calcification. Importantly, factors such as tumor necrosis factor-α and platelet derived growth factor-BB were also found to increase exosome production, leading to increased calcification of VSMCs in response to calcifying conditions. Conclusions:: This study identifies MVs as exosomes and shows that factors that can increase exosome release can promote vascular calcification in response to environmental calcium stress. Modulation of the exosome release pathway may be as a novel therapeutic target for prevention.

2 October 2014 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
LBLisa Bodei
Lisa Bodei
MKMark Kidd
Mark Kidd
GPGiovanni Paganelli
Giovanni Paganelli
CGChiara M. Grana
Chiara M. Grana
IDIgnat Drozdov
Ignat Drozdov
IMIrvin M. Modlin
Irvin M. Modlin

1 July 2012 in JACC
Verified
Journal Article
Closed access
AZANNA ZAMPETAKI
ANNA ZAMPETAKI
PWPeter Willeit
Peter Willeit
LTLindsey Tilling
Lindsey Tilling
IDIgnat Drozdov
Ignat Drozdov
MPMarianna Prokopi
Marianna Prokopi
MMManuel Mayr
Manuel Mayr

15 February 2013 in Circulation Research
Verified
Journal Article
Open access
PDF file
PWPeter Willeit
Peter Willeit
AZANNA ZAMPETAKI
ANNA ZAMPETAKI
KDKatarzyna Dudek
Katarzyna Dudek
DKDorothee Kaudewitz
Dorothee Kaudewitz
AKAlice King
Alice King
MMManuel Mayr
Manuel Mayr
Rationale:: MicroRNA (miRNA) biomarkers are attracting considerable interest. Effects of medication, however, have not been investigated thus far. Objective:: To analyze changes in plasma miRNAs in response to antiplatelet therapy. Methods and Results:: Profiling for 377 miRNAs was performed in platelets, platelet microparticles, platelet-rich plasma, platelet-poor plasma, and serum. Platelet-rich plasma showed markedly higher levels of miRNAs than serum and platelet-poor plasma. Few abundant platelet miRNAs, such as miR-24, miR-197, miR-191, and miR-223, were also increased in serum compared with platelet-poor plasma. In contrast, antiplatelet therapy significantly reduced miRNA levels. Using custom-made quantitative real-time polymerase chain reaction plates, 92 miRNAs were assessed in a dose-escalation study in healthy volunteers at 4 different time points: at baseline without therapy, at 1 week with 10 mg prasugrel, at 2 weeks with 10 mg prasugrel plus 75 mg aspirin, and at 3 weeks with 10 mg prasugrel plus 300 mg aspirin. Findings in healthy volunteers were confirmed by individual TaqMan quantitative real-time polymerase chain reaction assays (n=9). Validation was performed in an independent cohort of patients with symptomatic atherosclerosis (n=33), who received low-dose aspirin at baseline. Plasma levels of platelet miRNAs, such as miR-223, miR-191, and others, that is, miR-126 and miR-150, decreased on further platelet inhibition. Conclusions:: Our study demonstrated a substantial platelet contribution to the circulating miRNA pool and identified miRNAs responsive to antiplatelet therapy. It also highlights that antiplatelet therapy and preparation of blood samples could be confounding factors in case-control studies relating plasma miRNAs to cardiovascular disease.

10 May 2013 in Circulation Research
Verified
Journal Article
Closed access
PDF file
YLYiwen Liu
Yiwen Liu
IDIgnat Drozdov
Ignat Drozdov
RSRukshana Shroff
Rukshana Shroff
LBLeilani E. Beltran
Leilani E. Beltran
CSCathy Shanahan
Cathy Shanahan
Rationale:: Vascular calcification is prevalent in the aging population, yet little is known of the mechanisms driving age-associated vascular smooth muscle cell (VSMC) phenotypic change. Objective:: To investigate the role of nuclear lamina disruption, a specific hallmark of VSMC aging, in driving VSMC osteogenic differentiation. Methods and Results:: Prelamin A, the unprocessed form of the nuclear lamina protein lamin A, accumulated in calcifying human VSMCs in vitro and in vivo, and its overexpression promoted VSMC osteogenic differentiation and mineralization. During VSMC aging in vitro, prelamin A accumulation occurred concomitantly with increased p16 expression and osteogenic differentiation and was associated with increased levels of DNA damage. Microarray analysis showed that DNA damage repair pathways were significantly impaired in VSMCs expressing prelamin A and that chemical inhibition and siRNA depletion of the DNA damage response kinases ataxia–telangiectasia mutated/ataxia-telangiectasia– and Rad3-related effectively blocked VSMC osteogenic differentiation and mineralization. In coculture experiments, prelamin A–expressing VSMCs induced alkaline phosphatase activity in mesenchymal progenitor cells, and this was abrogated by inhibition of ataxia-telangiectasia–mutated signaling, suggesting that DNA damage induces the secretion of pro-osteogenic factors by VSMCs. Cytokine array analysis identified several ataxia-telangiectasia mutated–dependent senescence-associated secretory phenotype factors/cytokines released by prelamin A–positive VSMCs, including the calcification regulators bone morphogenetic protein 2, osteoprotegerin, and interleukin 6. Conclusions:: Prelamin A promotes VSMC calcification and aging by inducing persistent DNA damage signaling, which acts upstream of VSMC osteogenic differentiation and the senescence-associated secretory phenotype. Agents that target the DNA damage response and prelamin A toxicity may be potential therapies for the treatment of vascular calcification.